Multiple Manufacturers



Multiple Manufacturers

Retacrit HCPCS:


HCPCS Code Descriptor:

Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units


Q Code

Retacrit NDCs:

00069-1311-10, 00069-1318-10, 59353-0120-10, 59353-0220-10, 00069-1309-04, 00069-1308-10, 59353-0010-10, 59353-0004-10, 00069-1307-10, 00069-1306-10, 59353-0003-10, 00069-1305-10, 59353-0002-10, 59353-0120-01, 59353-0220-01

Primary Type:

Oncology Biosimilar

Generic/Specialty Status:


Route of Administration:


Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Retacrit:

RETACRIT is an Oncology Biosimilar drug manufactured by Vifor and administered via the Subcutaneous route of administration. The Q Code: Q5106 is aligned to the drug RETACRIT.

Retacrit is an injection used to treat patients with anemia caused by a variety of different factors. Retacrit can help treat low red blood cell count in patients with chronic kidney failure, patients receiving treatment for HIV, patients receiving chemotherapy for certain types of cancers, or patients about to undergo surgery. Retacrit works by signalling the bone marrow to produce more red blood cells. It can mimic the substance erythropoietin, which occurs naturally in the body and helps prevent anemia.


Q5106 Added Date:

July 1, 2018

Q5106 Effective Date:

January 1, 2020

Q5106 Termination Date:

HCPCS Active

We have not yet identified a manufacturer source of Retacrit billing and coding information.
Retacrit patient assistance information can be found through Pfizer Rx Pathways at the URL:
RETACRIT prescribing information can be found at the link below. Please reach out to us if you believe this information to be innacurate or out of date.
Our team has not yet identified a source of side effects information for RETACRIT. Please check back in a few weeks.